With 40 patients enrolled across two doses — 8.6 mg/kg and 10 mg/kg Q3W — CytomX has now closed the dose optimization cohorts for varsetatug masetecan faster than most ADC programs at comparable stages, and the data readout expected in the second half of 2026 carries disproportionate weight: it will simultaneously determine monotherapy dose selection and anchor the design of the first registrational trial in late-line colorectal cancer. That’s a lot riding on a single data package from a Phase 1 population.
The EpCAM target is the strategic gamble worth examining. EpCAM is broadly expressed across epithelial tumors — colorectal, gastric, ovarian, lung — but it is also expressed on normal epithelial tissue, which is precisely why prior EpCAM-directed therapies generated unacceptable toxicity and never advanced. CytomX’s PROBODY masking technology is the thesis: the ADC remains latent in systemic circulation and activates preferentially in the protease-rich tumor microenvironment. If that selectivity holds at the doses being optimized, Varseta-M is not just a colorectal cancer drug. The planned Phase 1 expansion into non-CRC indications in the second half of 2026 is an explicit bet on pan-tumor applicability — and the combination arm with bevacizumab suggests ambition to push into earlier lines, where patient volume is substantially larger than the refractory CRC setting.
The $346.7 million in cash — inflated by a $250 million equity raise closed in March — buys runway to at least mid-2028. That’s long enough to generate registrational trial entry data, bevacizumab combination readouts, and the first non-CRC signals. Revenue dropped sharply, from $50.9 million in Q1 2025 to $10.3 million this quarter, reflecting the wind-down of Bristol Myers Squibb and Amgen collaboration milestones rather than any operational deterioration. R&D spend held nearly flat at $19.2 million, with the modest increase driven by manufacturing scale-up for Varseta-M — exactly where the dollars should be going at this inflection point.
The single most consequential moment in this program’s near-term trajectory is the FDA alignment meeting planned for 2026. The agency’s agreement — or pushback — on registrational trial design in late-line CRC will determine whether the 1H 2027 trial start holds. Watch that interaction, not the 2H 2026 data presentation.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
